/HTBX

HTBX Stock - Heat Biologics, Inc.

Q: What is the analyst price target for HTBX?

Analyst price target information is not currently available for HTBX.

Q: What is HTBX's market cap?

Market capitalization information is not currently available for HTBX.

Healthcare|Biotechnology|AMEX

$2.38+0.42%

+$0.01 (+0.42%) • May 3

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.62

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HTBX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.30

52W High$10.85

52W Low$1.60

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$2.11M	$2.95M	$3.05M	$5.79M	$1.52M
Gross Profit	$2.11M	$2.95M	$3.05M	$5.79M	$1.52M
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-35,419,039	$-26,124,362	$-20,745,805	$-17,960,313	$-13,342,849
Net Income	$-35,400,807	$-26,049,737	$-20,017,568	$-15,733,854	$-11,841,671
Net Margin	-1675.5%	-883.7%	-656.5%	-271.6%	-779.1%
EPS	$-1.41	$-1.63	$-4.21	$-6.30	$-21.56

Company Overview

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Visit Website

Earnings History & Surprises

HTBX

Beat Rate

56%

Last 18 quarters

Avg Surprise

+5.4%

EPS vs Estimate

Beats / Misses

10/7

1 met exactly

Latest EPS

$-0.32

Q2 2022

EPS Surprise History

Q3 20

+47.0%

$-0.35vs$-0.66

Q4 20

-82.6%

$-0.42vs$-0.23

Q1 21

+94.3%

$-0.02vs$-0.35

Q2 21

-6.9%

$-0.31vs$-0.29

Q3 21

+13.3%

$-0.26vs$-0.30

Q4 21

0.0%

$-0.30vs$-0.30

Q1 22

-68.8%

$-0.54vs$-0.32

Q2 22

+33.7%

$-0.32vs$-0.49

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2022	May 16, 2022	$-0.49	$-0.32	+33.7%	✓ BEAT
Q1 2022	Mar 11, 2022	$-0.32	$-0.54	-68.8%	✗ MISS
Q4 2021	Nov 10, 2021	$-0.30	$-0.30	0.0%	= MET
Q3 2021	Aug 11, 2021	$-0.30	$-0.26	+13.3%	✓ BEAT
Q2 2021	May 5, 2021	$-0.29	$-0.31	-6.9%	✗ MISS
Q1 2021	Mar 25, 2021	$-0.35	$-0.02	+94.3%	✓ BEAT
Q4 2020	Nov 9, 2020	$-0.23	$-0.42	-82.6%	✗ MISS
Q3 2020	Aug 7, 2020	$-0.66	$-0.35	+47.0%	✓ BEAT
Q2 2020	May 15, 2020	$-0.70	$-0.77	-10.0%	✗ MISS
Q4 2019	Dec 31, 2019	—	$-0.41	—	—
Q4 2019	Nov 14, 2019	$-1.01	$-1.26	-24.8%	✗ MISS
Q3 2019	Aug 14, 2019	$-0.77	$-0.98	-27.3%	✗ MISS
Q2 2019	May 15, 2019	$-1.36	$-0.77	+43.4%	✓ BEAT
Q1 2019	Mar 28, 2019	$-1.36	$-1.05	+22.8%	✓ BEAT
Q4 2018	Nov 14, 2018	$-0.21	$-0.16	+23.8%	✓ BEAT
Q3 2018	Aug 14, 2018	$-0.18	$-0.27	-50.0%	✗ MISS
Q2 2018	May 15, 2018	—	$-5.24	—	—
Q1 2018	Mar 2, 2018	$-0.70	$-0.38	+45.7%	✓ BEAT
Q4 2017	Nov 13, 2017	$-0.90	$-0.60	+33.3%	✓ BEAT
Q3 2017	Aug 14, 2017	$-1.00	$-0.90	+10.0%	✓ BEAT